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Respiratory diseases are a major cause of mortality and 
morbidity worldwide. Current treatments offer no pros-
pect of cure or disease reversal. Transplantation of pul-
monary progenitor cells derived from human embryonic 
stem cells (hESCs) may provide a novel approach to 
regenerate endogenous lung cells destroyed by injury 
and disease. Here, we examine the therapeutic poten-
tial of alveolar type II epithelial cells derived from hESCs 
(hES-ATIICs) in a mouse model of acute lung injury. 
When transplanted into lungs of mice subjected to 
bleomycin (BLM)-induced acute lung injury, hES-ATIICs 
behaved as normal primary ATIICs, differentiating into 
cells expressing phenotypic markers of alveolar type I 
epithelial cells. Without experiencing tumorigenic side 
effects, lung injury was abrogated in mice transplanted 
with hES-ATIICs, demonstrated by recovery of body 
weight and arterial blood oxygen saturation, decreased 
collagen deposition, and increased survival. Therefore, 
transplantation of hES-ATIICs shows promise as an effec-
tive therapeutic to treat acute lung injury.
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19 January 2010. doi:10.1038/mt.2009.317
IntroductIon
The most distal region of the lung is a complex organization of 
alveoli where O2/CO2 exchange occurs. The alveolar epithelium is 
composed of two types of epithelial cells, type I (ATICs) and type 
II (ATIICs). The ATICs are large yet highly flattened cells with 
multiple apical surfaces that extend into adjacent alveoli. These 
cells, together with the endothelium of the surrounding capillar-
ies, form the very thin blood–air interface that is essential for O2/
CO2 exchange. In contrast, ATIICs are small cuboidal cells that 
secrete surfactant, which reduces surface tension, preventing col-
lapse of the alveolus. The lung is constantly exposed to environ-
mental toxins and pathogens that can destroy alveolar epithelial 
cells, in particular the thin injury prone ATICs. The ability of the 
injured alveolar epithelium to quickly and efficiently self-repair is 
therefore very important for maintaining normal pulmonary func-
tion. Although repair of the lung alveolar epithelium may include 
respiratory stem or progenitor cells not yet identified,1–3 it is well 
established that ATIICs have an important role in repopulating 
the injured alveolus by not only proliferating into new ATIICs but 
also by differentiating into ATICs.4
Despite the endogenous repair capacity of the alveolar epithe-
lium, it is often not sufficient. Inadequate, delayed, or impaired 
 re-epithelialization of the injured alveolus is regarded as a key 
factor in the pathogenesis of several life-threatening pulmonary 
diseases, including acute lung injury, acute respiratory distress 
syndrome, and chronic obstructive pulmonary disease. Current 
treatments for lung alveolar epithelial injury at best provide 
symptomatic relief but offer no prospect for repair of the damaged 
epithelium or preventing lung fibrosis. Consequently, there is a 
pressing need for the development of novel therapies that facili-
tate the regeneration of alveolar epithelium destroyed by acute 
and chronic lung diseases.
Embryonic stem cells (ESCs) are self-renewing pluripotent 
cells, which can be induced to differentiate into a wide range of 
different cell types.5,6 The potential use of ESCs in the treatment 
of pulmonary diseases has evoked extensive interest in develop-
ing methods that promote ESC differentiation into lung progeni-
tor cells. Because of their ability to proliferate and to differentiate 
into ATICs, ATIICs derived from ESCs may be promising as a 
transplantable source of cells that could be used therapeutically 
to treat distal lung injury. Recently, ESCs were shown to differ-
entiate into ATIICs in culture,7–9 but these procedures yielded a 
mixture of ESC derivatives with only a small percentage of the 
cells being ATIICs. A mixed population of cells will not be suit-
able for transplantation, and remaining pluripotent cells in these 
mixed cultures carry a significant risk of producing teratomas 
after transplantation. Therefore, a prerequisite for using ATIICs 
therapeutically is to develop a method that will routinely yield a 
pure population of ATIICs. Our laboratory has recently achieved 
this goal by generating stable hESC lines that can be differentiated 
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and enriched into a pure population of ATIICs.10 The purpose of 
this investigation is to determine in a mouse model of bleomycin 
(BLM)-induced acute lung injury if transplanted ATIICs derived 
from hESCs (hES-ATIICs) will differentiate and functionally 
repair the epithelium of the acutely injured alveolus.
results
stable transfected hesc lines
Aquaporin-5 (AQP5) is a mercury-sensitive water channel that is 
found in the apical membrane of ATICs with little to no expres-
sion in ATIICs.11,12 T1α is a cell surface mucin-like glycoprotein 
with no known function that is expressed by ATICs but not 
ATIICs.13–16 Both AQP5 and T1α are used frequently as pheno-
typic markers for ATICs. Therefore, to visualize the differentia-
tion of hES-ATIICs into ATICs two new stable human embryonic 
stem cell (hESC) lines (AQP5P.65 and T1αP.53) were generated in 
which either AQP5 or T1α transcriptional promoters were cloned 
upstream of the LacZ gene (Figure 1). The construction of the 
vectors and the generation and characterization of the stable hESC 
lines are described in Materials and Methods.
Proliferation and differentiation of hes-AtIIcs in vitro
One of the important biological functions of ATIICs is to pro-
liferate and to serve as progenitor cells for ATICs. To determine 
whether hES-ATIICs proliferated in vitro, hES-ATIICs generated 
from the SPC/NEO.74 hESC line10 were cultured with mouse 
embryonic fibroblast–conditioned Dulbecco’s modified Eagle’s 
medium (DMEM). Recombinant keratinocyte growth factor 
(rhKGF), which is an ATIIC growth factor,17 was added to some 
of the cultures to determine whether rhKGF could be used to 
enhance proliferation of hES-ATIICs. After 7 days of culture, the 
number and size of the hES-ATII colonies had increased signifi-
cantly (Figure 2a,b). In the absence of rhKGF, each well contained 
on average 12 colonies with each colony comprising 7–12 cells. 
The addition of rhKGF for 7 days caused the number and size 
of the hES-ATII colonies to increase (average 35 colonies/well 
and 25–35 cells/colony) (Figure 2b). These results show that 
hES- ATIICs proliferate in vitro and that the addition of rhKGF 
significantly increases the proliferation of the  hES-ATIICs in 
culture.
To assess the ability of hES-ATIICs to differentiate into ATICs 
in vitro, hES-ATIICs and control primary human ATIICs were 
cultured with DMEM and left to spontaneously differentiate. 
Differentiation was assessed by real-time quantitative reverse 
transcriptase-PCR (QRT-PCR) using specific primer pairs to 
detect gene expression of AQP5 and T1α. As shown in Figure 2c, 
cultured hES-ATIICs and primary human ATIICs exhibited 
increased expression of RNA specific for AQP5 and T1α, indicat-
ing that hES-ATIICs differentiate into ATICs in vitro at a similar 
rate as do primary ATIICs (Figure 2c). To confirm these findings, 
hES-ATIICs derived from the AQP5P.65 and T1αP.53 cell lines, 
were cultured as above and stained for LacZ expression. In sup-
port of the data shown in Figure 2c, fresh hES-ATII cultures did 
not express LacZ (day 0), but did exhibit increased LacZ expres-
sion over time with essentially all cells expressing some level of 
LacZ after 8 days of culture (Figure 2d). Collectively, the QRT-
PCR and LacZ data indicate that hES-ATIICs spontaneously dif-
ferentiate in culture in the absence of mouse embryonic fibroblast 
to cells expressing ATICs phenotypic markers.
transplantation and in vivo differentiation  
of hes-AtIIcs in a mouse model of acute lung injury
The antineoplastic drug BLM when administered intratracheally 
to mice primarily targets the pulmonary epithelium and repro-
duces the pattern and numerous features of acute lung injury in 
humans, including rapid onset of inflammation, alveolar injury 
that heals with fibrosis, and severe hypoxemia.18 As described in 
Materials and Methods, female SCID/C57BL/6 mice were sub-
jected to BLM-induced acute lung injury. Following BLM treat-
ment, hES-ATIICs were administered by intratracheal intubation 
into the mouse terminal airways, and end point lung sections 
were examined by immunohistochemistry. To examine whether 
transplantation efficiency would be affected by the time in which 
cell therapy was provided, hES-ATIICs were administered 1 or 
2 days following BLM-induced acute lung injury. Transplanted 
hES-ATIICs were identified using an antihuman pro-SPC anti-
body and a mouse antihuman nuclei monoclonal antibody.19,20 
As shown in Figure 3, control mice that received either saline or 
BLM, but not hES-ATIICs showed no antihuman nuclei stain-
ing. In contrast, lung tissue from mice that were subjected to 
acute lung injury and administered hES-ATIICs did show sig-
nificant antihuman nuclei staining. In addition, most of the cells 
positive for human nuclei co-stained with antihuman pro-SPC 
(Figure 3 and Table 1), demonstrating that the hES-ATIICs were 
capable of being transplanted into the BLM-injured alveoli. The 
time that the hES-ATIICs were administered (1 or 2 days after 
lung injury) did not affect significantly the percentage of SPC+/
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Figure 1 structure of surfactant Protein c (sPc) promoter–neor 
transgene vectors. The structures of the three SPC promoter–NEor 
transgene vectors used to generate hES-ATIIC lines are schematically dia-
gramed. Each diagram is drawn to depict relevant information, so they 
are not to exact scale. The details regarding construction of the trans-
gene vectors are described in Materials and Methods. (a) The original 
vector (3′hprt.SPCP.NEor) used to generate a pure population of the 
hES-ATII cells.10 A 3.8-kb human genomic DNA fragment containing the 
SPC promoter and 170 bp of noncoding sequence of exon 1 was cloned 
into the targeting vector backbone,45 containing the hypoxanthine 
phosphoribosyl transferase 3′-cassette (3′-HPRT), the puromycin-resis-
tant gene (Puro), the K14Agouti transgene (Ag), and a LoxP site (open 
arrow). The Neor gene was added downstream of the SPC promoter. 
The other two transgene vectors were generated to allow the differen-
tiation of hES-ATIICs to ATICs to be detected by LacZ staining. (b) This 
vector was constructed by adding 1.26-kb human AQP5 promoter and 
3.1-kb LacZ cDNA cassette into 3′hprt.SPCP.NEor vector. (c) This vector 
was generated by cloning 1.2-kb human T1α promoter and 3.1-kb LacZ 
complementary DNA cassette into 3′hprt.SPCP.NEor vector. The EcoRI 
site located downstream of Neor gene was used to linearize the plasmid 
before transfection of the hES cells.
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human nuclei+ cells found in the mouse end point lung sections 
(Table 1). Lung tissue sections from saline-treated control mice 
that were administered hES-ATIICs were devoid of antihuman 
nuclei staining, indicating that lung injury is required for trans-
plantation of hES-ATIICs to occur. In addition, BLM-injured 
mouse lungs that were provided human monocytes rather than 
hES-ATIICs also exhibited no antihuman nuclei staining, sug-
gesting that transplantation and possible cell engraftment was 
specific for the hES-ATIICs.
Although the majority of the transplanted hES-ATIICs 
 co-stained positive for both human nuclei and SPC, there were 
numerous examples of transplanted cells staining positive for 
human nuclei but not for SPC within the counted area of 400 
SPC+ cells (Figure 3 and Table 1), suggesting that a number of 
the transplanted hES-ATIICs had differentiated into ATICs within 
9 days after transplantation. Immunohistochemistry of lung sec-
tions stained for anti-T1α supported this observation (Figure 4a). 
Moreover, LacZ+ cells in similar numbers as the SPC−/nuclei+ 
cells were observed in the lungs of BLM-treated mice that received 
hES-ATIICs derived from the T1αP.53 and AQP5P.65 cells lines, 
but not in the saline or BLM control lungs (Figure 4b). Collectively, 
these data demonstrate that the hES-ATIICs have the ability to 
transplant into the damaged alveoli of BLM acutely injured mouse 
lungs and to differentiate into cells expressing phenotypic markers 
of ATICs.
transplantation of hes-AtIIcs abrogates BlM-
induced acute lung injury in mice
Following intratracheal exposure to BLM, hES-ATIICs were 
transplanted into the injured alveoli of the mouse to determine 
whether the hES-ATIICs could prevent or reverse the acute 
lung damage caused by BLM. Direct initial damage to the alve-
olar epithelial cells occurred followed by acute inflammation 
within 24 hours. Ten days after BLM-challenge, ~50–75% of the 
lung alveolar epithelium was severely injured, noted by inter-
stitial thickening, alveolar collapse, cystic air spaces, extensive 
interstitial infiltration of inflammatory cells, and collagen depo-
sition (Figure 5a). Transplantation of hES-ATIICs, after BLM-
challenge greatly reduced the extent of damage within the lung 
as evidenced by only a few isolated, small areas of injured tissue 
surrounded by much larger areas of normal alveolar structure 
(Figure 5a). In contrast, transplantation of human monocytes 
after BLM-challenge did not reduce BLM-induced lung injury. 
Hydroxyproline content was also determined to evaluate BLM-
mediated collagen deposition in the lungs (Figure 5b). The 
hydroxyproline content was increased significantly after BLM 
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Figure 2 Proliferation and differentiation of hes-AtIIcs in vitro. (a) Shown are representative phase-contrast images of cultured hES-ATIICs. Small 
hES-ATIIC-derived colonies containing 7–10 cells were observed in cultures on matrigel-coated dishes with mouse embryonic fibroblast–conditioned 
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (bottom image, original magnification = ×200). Large hES-ATIIC-derived 
colonies containing 25–35 cells were seen in the cultures treated with 30 ng/ml of rhKGF (upper image, original magnification = ×200). (b) There 
were significantly more total colonies in the rhKGF-treated cultures compared to the untreated (12 colonies/well) (P < 0.001; n = 7). (c) Expression 
of markers for ATICs during differentiation of hES-ATIICs. Aquaporin-5 (AQP5)- and T1α-specific quantitative reverse transcriptase-PCR was performed 
using total RNA isolated from differentiating cultures of hES-ATIICs. Bar graphs depict RNA expression levels of AQP5 and T1α in the cultures on day 
0, 2, 4, 6, and 8 (n = 7). (d) Differentiation of ATII cells to ATI cells as visualized by LacZ staining. A few LacZ+ cells (blue-green) were seen in the dif-
ferentiating culture of hES-ATII cells as early as on day 2. The number of LacZ+ cells significantly increased over time, with 100% of the cells showing 
at least some LacZ+ staining on day 8 (original magnification= ×200).
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exposure and remained elevated when treated with human 
monocytes. In contrast, the amount of hydroxyproline in the 
BLM-injured lungs that received hES-ATIICs was reduced 
and near the hydroxyproline content found in the saline 
control lungs.
BLM-induced lung injury is associated with significant loss 
of body weight. To determine whether the transplantation of 
hES-ATIICs could either arrest or reverse the loss of weight in 
the BLM-challenged animals, mice treated with or without hES-
 ATIICs were weighed for 10 days after BLM-challenge (Figure 5c). 
Intratracheal administration of BLM caused a significant weight 
loss by day 2. The loss of weight in the BLM-injured mice that 
did not receive hES-ATIICs or were provided with human mono-
cytes continued over time and by day 10 had lost 28% of their 
initial body weight. The BLM-injured mice that were treated with 
hES-ATIICs also experienced an initial drop in weight, but by 
day 6 these mice experienced a significant increase in weight, and 
by day 10 they had recovered 95% of their weight before BLM-
induced lung injury (Figure 5c).
recovery of lung tidal volume and blood  
arterial oxygen saturation in BlM-treated  
mice transplanted with hes-AtIIcs
As demonstrated by the experimental results shown in Figure 5a,b, 
exposure of the lungs of severe combined immunodeficient 
(SCID) mice to BLM caused extensive alveolar epithelial cell 
damage, resulting in airway structure distortion, interstitial tissue 
thickening, and collagen deposition. In contrast, most of the alve-
olar damage was arrested or repaired if hES-ATIICs were admin-
istered to these mice following BLM-induced acute lung injury. 
Therefore, it was hypothesized that normal lung function could be 
table 1 relative human type II alveolar cell content in bleomycin-
mouse lung tissue
 sPc+ sPc+/nuclei+ sPc+/nuclei− sPc+/nuclei+%
Saline-SCID 200 – 200 0
BLEO-SCID 200 – 200 0
BLEO-SCID/ATII D1 400 78 (43)a 322 19.5
BLEO-SCID/ATII D2 400 86 (42)a 314 21.5
Abbreviations: BLEO, bleomycin; SCID, severe combined immunodeficiency.
See Materials and Methods for details.
aNo. of SPC−/Nuclei+ cells in counted areas.
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Figure 3 Immunofluorescent staining of hes-AtIIcs transplanted in the lungs of bleomycin (BlM)-challenged mice. Shown are representative 
slides of lung sections from BLM-challenged mice with and without transplanted hES-ATIICs. The slides were immunostained with a mouse antihuman 
nuclei monoclonal antibody and rabbit antihuman pro-SPC antibody as described in Materials and Methods. Mouse and human nuclei are stained 
blue by 4’,6-diamidino-2-phenylindole (DAPI); cells of human origin (hES-ATIICs) are stained red by the antihuman nuclei monoclonal antibody; 
both mouse and human cells expressing SPC (ATIICs) are stained green by the rabbit antihuman pro-SPC. Human cells expressing SPC (hES-ATIICs) 
are co-stained red and green giving a yellowish color. As expected the number of mouse ATIICs that expressed SPC (green) in the control lung sec-
tion (control: original magnification = ×400) was greatly decreased in the BLM-challenged mouse lung (BLM: original magnification = ×400). Human 
specific (red) cells were identified only in the BLM-challenged lungs that had been transplanted with hES-ATIICs (BLM/ATII day 1 and BLM/ATII day 
2: original magnification = ×400). Most of the human-specific cells co-stained for SPC, indicating that these cells are transplanted hES-ATIICs (indi-
cated by white arrows in the far right panels BLM/ATII day 1 and BLM/ATII day 2). As depicted in the BLM/ATII day 2, there were some transplanted 
human cells that were not SPC+ (indicated by yellow arrows), suggesting that these cells were ATICs that had differentiated from the transplanted 
hES-ATIICs.
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restored to the BLM-challenged mice after transplantation with 
hES-ATIICs. To test this hypothesis, lung tidal volumes and blood 
arterial oxygen saturation levels were measured in mice that were 
treated with and without hES-ATIICs following BLM-induced 
acute lung injury. As illustrated in Figure 6a, the lung tidal vol-
ume during spontaneous respiration was significantly decreased 
after BLM lung injury; in contrast, the lung tidal volume in the 
BLM-challenged mice that were treated with hES-ATIICs was 
completely normal. Similar to the lung tidal volume, the blood 
oxygen levels in the BLM-challenged mice declined significantly 
4 days after BLM lung injury (Figure 6b) and by day 13 all the 
BLM-treated mice succumbed to respiratory failure (Figure 6c). 
Impressively, the BLM-injured mice that had been transplanted 
with hES-ATIICs exhibited normal blood arterial oxygen satura-
tion levels at 4 days after BLM-challenge. To determine whether 
transplantation of the hES-ATIICs could provide a long-term 
benefit and to ensure that administration of these cells would not 
lead to teratoma formation, 28 female SCID mice were exposed to 
3.5 units/kg of BLM as before; 6 of these mice received hES-ATIICs 
after BLM exposure. None of the mice subjected to BLM-induced 
acute lung injury and not provided treatment with hES-ATIICs 
lived >13 days after BLM exposure (Figure 6c). In stark contrast, 
all the BLM-challenged mice that were treated with hES-ATIICs 
remained alive and healthy and without teratoma formation for 
the entire duration of the study (300 days). Collectively, these data 
indicate that the BLM-injured alveolar epithelium can be func-
tionally repaired long-term by transplantation of hES-ATIICs.
dIscussIon
Current treatments for lung injury do very little to induce cellular 
repair or to prevent the onset of lung fibrosis. Considerable inter-
est has developed in the potential use of stem cells to repair lung 
epithelium damaged or destroyed by injury and disease. Initial 
investigations were performed using bone marrow–derived stem 
cells, which at first were thought to engraft and differentiate into 
pulmonary epithelial cells following lung injury.21–26 However, 
subsequent studies revealed that the original conclusions drawn 
from these rodent lung injury models were incorrect due to stain-
ing artifacts.27,28 It is now generally agreed that following lung 
injury little, if any, engraftment of lung cells originating from the 
bone marrow occur.
Because of their ability to differentiate into essentially any cell 
in the body, ESCs may provide an attractive alternative to bone 
marrow stem cells in regenerating lung tissue. However, much of 
the enthusiasm for using hESCs to regenerate damaged tissue has 
been tempered by the observation that direct application of hESCs 
in vivo may cause teratoma formation, resulting in a possible lethal 
outcome.29,30 Primary ATIICs have shown promise in their ability 
to reverse lung injury in rats subjected to BLM treatment,31 indi-
cating that endogenous lung cells with progenitor cell properties 
may prove useful in repairing damaged or diseased lung tissue. 
However, it will be extremely difficult to obtain sufficient quanti-
ties of human primary ATIICs that could be used for treatment 
of lung injury and disease. Accordingly, our laboratory recently 
developed a reliable culture and genetic selection procedure to 
generate a pure population of transplantable ATIICs from hESCs.10 
In the current study, hES-ATIICs were evaluated in a mouse model 
of BLM-induced acute lung injury for their ability to functionally 
repair damaged lung tissue without causing teratoma formation.
As with whole-organ transplantation, hES-ATII cells may experi-
ence immune rejection when transplanted into the lungs of allogeneic 
recipients. Immune rejection of transplanted allogeneic hES-ATII 
cells could be controlled by immunosuppresive drugs; or possibly 
in the near future by using ATIICs generated from induced pluripo-
tent stem cells derived from the patient’s own dermal fibroblasts. No 
matter how graft rejection issues with allogeneic cells are resolved, 
proof of principal transplantation studies in animal models such as 
those in this investigation must be performed before any therapeutic 
use of hES-ATII cells can be proposed. Xenogenic transplantation of 
human cells into recipient animals with a fully intact immune sys-
tem may also cause rejection of the hES-ATIICs. Therefore, to evalu-
ate the therapeutic potential of hES-ATIICs in acute lung injury, 
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Figure 4 Identification of AtIcs differentiated from transplanted 
hes-AtIIcs. (a) Representative slides are shown (original magnifica-
tion = ×200) of lung sections from BLM-challenged mice with and 
without transplanted hES-ATIICs that were immunostained by mouse 
antihuman nuclei monoclonal antibody (red) and rabbit antihuman 
T1α antibody (green) as described in Materials and Methods. Slides 
were nuclear-counterstained by 4’,6-diamidino-2-phenylindole (DAPI) 
(blue). Cells expressing T1α were observed in control lungs and BLM-
challenged lungs, because the anti-T1α antibody recognized both human 
and mouse ATI cells (control and BLM panels). Cells expressing both T1α 
and human-specific nuclei proteins were only present in BLM-challenged 
lungs that had been transplanted with hES-ATIICs (BLM/ATII panel). 
Human cells expressing T1α are thought to be ATICs differentiated from 
the transplanted hES-ATIICs (indicated by arrows). (b) Shown are slides 
from control lung sections and BLM-challenged mice with and without 
transplanted hES-ATIICs generated from the AQP5P.65 and T1αP.53 cell 
lines. Slides were stained for LacZ expression as described in Materials 
and Methods. Cells expressing LacZ were found in the BLM-injured lungs 
when transplanted with hES-ATIICs from both hES-ATII cell lines, support-
ing the data shown in Figure 3 and a that some of the transplanted hES-
ATIICs had or were in the process of differentiating to ATICs (note that 
the LacZ figures shown were selected so that several different LacZ+ cells 
could be visualized in a single panel). However, most panel photographs 
had only one to two LacZ+ cells—similar to the number of SPC−/human 
nuclei+ cells (Figure 3) and the T1α+ cells in a.
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immune-compromised SCID mice were used to prevent rejection 
of the transplanted hES-ATIICs. Because of their severely impaired 
immune system, SCID mice also provided an excellent model32 in 
which to evaluate the hES-ATII-treated mice for teratoma formation 
should there be remaining hESCs in the ATIIC genetically selected 
cultures. A relatively high dose of BLM (3.5 units/kg) was given to 
SCID mice by intratracheal intubation. This dose of BLM was used 
so that at the time of hES-ATIIC transplantation the lung damage 
resembled that of acute lung injury, including extensive interstitial 
inflammatory cell infiltration, interstitial thickening, and collagen 
deposition. Moreover, 3.5 units/kg of BLM caused sufficient lung 
injury so that endogenous cell repair was negligible and ineffective, 
leading to 100 % mortality of all BLM-treated mice by 13 days after 
BLM-challenge, thereby allowing the impact of transplanted hES-
ATIICs on survival to be evaluated without possible confounding 
results due to endogenous lung stem cell repair.
Failure to efficiently repopulate the alveolar epithelium after 
injury is a major factor in the development of pulmonary fibro-
sis.33 Alveolar cell damage results in denuded epithelial basement 
membranes and the release of chemoattractant molecules, which 
mediate the migration of fibroblasts into the alveolar space and 
the development of intra-alveolar fibrosis. Although it could not 
be definitively proven in our studies that the transplanted hES-
 ATIICs were physically engrafted into the mouse alveolar epithelial 
basement membranes denuded by BLM injury, there was consid-
erable evidence to support this possibility, such as: (i) numerous 
hES-ATIICs remained in the mouse lung sections obtained 10 days 
following acute injury even after exhaustive lavage, (ii) many of the 
transplanted hES-ATIICs had differentiated into cells expressing 
phenotypic markers of ATICs, (iii) no hES-ATIICs were found 
when transplanted into mouse lungs not subjected to BLM-
induced acute injury, i.e., lack of denuded basement membranes 
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Figure 5 transplantation of hes-AtIIcs reduced BlM-induced acute lung injury in mice. (a) Shown are hematoxylin–eosin (H&E) and Sirius 
Red stained slides of representative end point (day 10) lung sections from BLM-challenged mice with and without transplanted hES-ATIICs (original 
magnification = ×200). H&E and Sirius Red staining were performed as described in Materials and Methods. BLM-challenge caused extensive alveolar 
structural damage (50–75%) with extensive cellular infiltration, interstitial thickening (H&E/BLM, second panel) and collagen deposition (Sirius Red/
BLM, second panel) compared with control lungs treated with saline (H&E/control and Sirius Red/control far left panels). Lungs that were transplanted 
with hES-ATIICs 1 (BLM/ATII day 1) or 2 days (BLM/ATII day 2) after BLM-induced acute lung injury showed significantly reduced damage with only a 
few (5%) isolated areas of the lung found to exhibit signs of cellular infiltration, interstitial thickening, and collagen deposition. Lungs that were trans-
planted with human monocytes 1 day after lung injury showed the same extensive alveolar structural damage (50–75%) as the BLM-treated lungs not 
transplanted with hES-ATIICs. (b) Collagen deposition was also evaluated by analysis of the hydroxyproline content in the experimental mouse lungs 
as described in Materials and Methods. The hydroxyproline content was significantly increased from 53.36 ± 2.48 to 94.58 ± 2.99 μg/lung 10 days 
after BLM exposure (P < 0.001, n = 10). As was similarly concluded visually by Sirius Red staining, transplantation of hES-ATIICs 1 (62.72 ± 5.89 μg/
lung; P < 0.001, n = 10) or 2 days (65.1 ± 7.17 μg/lung; P < 0.001, n = 10) after BLM-challenge significantly reduced collagen deposition to levels 
near that of uninjured lungs. In support of the Sirius Red staining data, monocyte transplantation did not result in reduction of hydroxyproline con-
tent (96.49 ± 3.18 μg/lung) in the BLM-injured mouse lungs. (c) This graph illustrates the percentage of body weights of control saline-treated mice 
(red), to that of BLM-treated mice (dark blue), and BLM-injured mice provided human monocytes (light blue) or hES-ATIICs 1 (black) or 2 (green) 
days after BLM–acute lung injury. The body weight of BLM-challenged mice as well as BLM-challenged mice transplanted with human monocytes was 
decreased significantly over time and by day 10 was only 72% of the body weight of the control mice (day 6: P < 0.001, n = 8; day 8: P < 0.001, n = 
8; day 10: P < 0.001, n = 8). Weight loss occurred initially as well in the mice that were transplanted with hES-ATIICs 1 or 2 days after BLM exposure. 
However, by 4 days after lung injury these mice started to show body weight recovery, and by day 6 the body weights of the mice transplanted with 
hES-ATIICs were significantly increased compared to the BLM-injured mice (day 6, hES-ATIICs day 1, P < 0.05, n = 8) (day 6, hES-ATIICs day 2, P < 
0.05, n = 8). By day 10, the BLM-challenged mice transplanted with hES-ATIICs had recovered ~95% of their initial body weights.
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to facilitate engraftment, and (iv) in contrast to the hES-ATIICs, 
human monocytes did not remain in the BLM-injured mouse 
lungs following transplantation. Therefore, re-epithelialization of 
BLM-damaged alveolar epithelium by engrafted hES-ATIICs may 
have prevented the development of severe fibrosis observed in the 
BLM-injured mice that were not treated with hES-ATIICs.
Although our data strongly argue that engraftment and dif-
ferentiation of hES-ATIICs play a major role in repairing or pre-
venting tissue damage caused by BLM, it is unlikely that these 
two events alone accounted for all the noted therapeutic benefits 
provided by the hES-ATIICs. Instead, it is probable that engraft-
ment is one part of a complex series of biological events initiated 
by the transplantation of hES-ATIICs. For example, transplan-
tation of hES-ATIICs prevented or reversed BLM-induced lung 
damage in some areas of the alveolar epithelium that did not har-
bor engrafted hES-ATIICs. Bone marrow stem cells have been 
reported to cause the release or production of anti-inflammatory 
cytokines, thereby causing some reversal of lung injury despite 
their lack of engraftment.34–36 Perhaps transplanted hES-ATIICs 
secrete factors that are either anti-inflammatory or cause the 
release of anti- inflammatory molecules as well, thereby arrest-
ing the inflammation and fibrosis caused by BLM. In addition, 
even though endogenous progenitor or stem cells of the lung 
were not sufficient to repair or arrest tissue damage in our model 
of acute lung injury, it is possible that hES-ATIICs through the 
release of growth factors trigger the expansion of endogenous 
lung progenitor or stem cells that in concert with the hES-ATIICs 
 re- epithelialize the damaged alveolar epithelium.
Whether or not lung injury prevention or repair was depen-
dent on engraftment and differentiation of the transplanted hES-
ATIICs, it is unequivocal that their presence in the damaged 
alveolus provided a major therapeutic benefit to mice subjected to 
BLM–acute lung injury. For example, the loss of body weight by 
BLM-treated mice was irreversible resulting in death if the mice 
were not provided hES-ATIICs. However, when given hES- ATIICs 
the BLM-injured mice experienced an almost complete reversal 
of weight loss, indicating that the transplanted hES-ATIICs were 
required for body weight recovery. In addition, treatment with 
hES-ATIICs not only prevented or reversed visual hallmarks of 
pulmonary injury, but also restored near normal lung function to 
mice subjected to BLM–acute lung injury. Moreover, this benefit 
was specific for hES-ATIICs, as treatment with purified human 
monocytes did not prevent or reverse BLM-induced acute lung 
injury. Importantly, the therapeutic benefits provided by hES-
 ATIICs were long-term and without teratoma formation, indi-
cating that the cultures of hES-ATIICs used in these studies were 
highly purified and free of any remaining hESCs. Staining of the 
long-term lung sections indicated that ~5% of the hES-derived 
ATI or ATII cells remained in the lungs 300 days after BLM injury 
and transplantation (data not shown). It has been estimated that 
the turnover of the adult mammalian alveolar epithelium is 4–5 
weeks (ref. 37). Therefore, the percentage of transplanted human 
lung epithelial cells remaining in the mouse lungs at 300 days 
appears reasonable, given that the lung alveolar epithelium was 
almost fully repaired by 10 days preventing long-term prolifera-
tion of the engrafted hES-ATII cells. Further investigations are 
needed to determine the proliferation capability of hES-ATII cells 
in vivo.
In summary, the data from this study have shown for the first 
time that lung progenitor ATIICs derived from hESCs can indeed 
be transplanted into acutely damaged alveoli of mice and that 
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Figure 6 Pulmonary function and survival rate of BlM-challenged 
mice with and without transplanted hes-AtII cells. (a) Shown graphi-
cally are the lung tidal volumes that were determined during sponta-
neously breathing using a rodent pulmonary plethysmograph (Buxco 
Electronics) as described in Materials and Methods. The tidal volumes 
measured 10 days after acute lung injury were significantly reduced in 
the BLM-challenged mice (0.179 ± 0.02 ml) compared to normal con-
trol mice (0.242 ± 0.007 ml) (P < 0.001, n = 8/group). In contrast, when 
the BLM-challenged mice were transplanted with hES-ATIICs 1 day after 
BLM-induced acute lung injury their lung tidal volumes had returned to 
normal (0.241 ± 0.002 ml) by day 10 after BLM-challenge (P = 0.605, n = 
8/group). (b) Shown graphically are the blood arterial oxygen saturation 
levels recorded on days 4, 7, and 10 after BLM-challenge using a small 
rodent oximeter sensor mounted on the thigh of each mouse (MouseoX; 
STARR Life Sciences) as described in Materials and Methods. Compared 
to normal mice (98.0%), the blood arterial oxygen saturation levels in the 
BLM-challenged mice (79.55%) were significantly decreased by day 4 after 
BLM-challenge (P < 0.001, n = 12/group) and continued to decrease for 
the remainder of the 10 day study (75.66% on day 7 and 69.7% on day 
10) (day 7, P < 0.001, n = 12/group) (day 10, P < 0.001, n = 12/group). In 
contrast, the BLM-challenged mice that were transplanted with hES-ATIICs 
showed complete recovery of normal arterial oxygen saturation levels by 
4 days after BLM-induced acute lung injury (P = 0.673 normal versus BLM 
mice treated with hES-ATIICs, n = 12/group) (P < 0.001 BLM mice versus 
BLM mice treated with hES-ATIICs, n = 12/group). (c) Percent survival of 
BLM-challenged mice with and without transplantation of hES-ATIICs is 
graphically presented. During the first 7 days following BLM-challenge 5 
of 22 mice had died. Between 7 and 10 days, another 5 mice from this 
group of 22 had died. All of the remaining BLM-treated mice (12) had 
died by 13 days after BLM-induced acute lung injury. In contrast, all of 
the BLM-challenged mice that were transplanted with hES-ATIICs survived 
(6/6). In addition, all 6 of these mice remained completely healthy to the 
end point of the study (300 days).
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these hES-ATIICs arrested or reversed BLM-induced  pathological 
changes of acute lung injury, including fibrosis. Moreover, the 
therapeutic benefits provided by the transplantation of hES- ATIICs 
were long- term and without the development of teratomas.
MAterIAls And Methods
Construction of human SPC promoter–NEOr+T1α/AQP5 promoter–LacZ 
transgene vectors. The 3′hprt.SPCP.NEOr vector containing the human 
SPC promoter–NEOr transgene and puromycin-resistant gene (Figure 1a) 
was used to generate two new transgene vectors, 3′hprt.SPCP.NEOr.
AQP5P.LacZ (Figure 1b) and 3′hprt.SPCP.NEOr.T1α.LacZ (Figure 1c). To 
clone the AQP5 or T1α promoter–LacZ transgene cassettes into the 3′hprt.
SPCP.NEOr vector, the NEOr gene and the cloning NdeI site were removed 
and replaced with a NEOr gene containing an AseI restriction cloning site 
and HpaI, NdeI, and EcoRI restriction sites were downstream of the NEOr 
gene. Either a 1.2-kb human genomic DNA fragment containing the T1α 
promoter and 202 bp of noncoding sequence of exon 1 of the T1α gene 
(ref. 38) or a 1.26-kb genomic DNA fragment containing the human AQP5 
promoter (−1,260 to −1) (ref. 39) was cloned into the engineered HpaI and 
NdeI sites of the 3′hprt.SPCP.NEOr vector. A 3.1-kb LacZ cDNA was cloned 
at the NdeI restriction site downstream of either the AQP5 or T1α promot-
ers. The 3′hprt.SPCP.NEOr.T1αP.LacZ and 3′hprt.SPCP.NEOrAQP5P.LacZ 
vectors were linearized by EcoRI before transfection.
Transfection and selection of hESC lines. The National Institutes of Health 
approved hESC line, H9.2 (passages 40–65) (WiCell, Madison, WI), was 
used throughout this study. Undifferentiated hES cells cultured on mitoti-
cally inactivated mouse embryonic fibroblasts in 6-well plates were trans-
fected with either the 3′hprt.SPCP.NEOr.T1αP.LacZ or the 3′hprt.SPCP.
NEO.AQP5P.LacZ vectors using the Nucleofector II (Amaxa, Gaithersburg, 
MD), and selected in the presence of 0.25 µg/ml puromycin (Sigma, 
St Louis, MO) for 14 days as described previously.10 Surviving hES clones 
were examined for the Neor and LacZ transgene by PCR analysis. The hES 
clones T1α.LacZ.53 and AQP5P.LacZ.65 containing only a single copy of 
the corresponding transgene were selected for further analysis.
In vitro differentiation, selection, culture, and characterization of hES-
ATIICs. The hESC lines, SPCP.NEO.74, T1α.LacZ.53, and AQP5P.LacZ.65, 
were cultured on matrigel-coated 10-cm plates and allowed to spontane-
ously differentiate in differentiation medium composed of 80% knock-out 
DMEM (Gibco Invitrogen, Carlsbad, CA), 20% fetal bovine serum, 1% 
nonessential amino acids, 1 mmol/l l-glutamine, 100 μg/ml penicillin, and 
100 μg/ml streptomycin. The hES-ATIICs in the cultures were selected with 
G418 (20 µg/ml; Gibco Invitrogen) as reported previously.10 For transplan-
tation, G418-selected hES-ATII cells on day 14 were trypsinized and then 
seeded back onto fresh matrigel–coated 10-cm culture plates with differ-
entiation medium. The hES-ATII cells were harvested the following day, 
washed once with normal saline, and resuspended in normal saline (107 
cells/ml). For spontaneous differentiation studies, G418-selected hES-
 ATIICs as well as normal human ATIICs were seeded onto 6-well culture 
plates with DMEM (Gibco Invitrogen) containing 10% fetal bovine serum 
(day 0) with medium change every other day. The primary ATIICs were 
isolated and cultured as previously described.40 ATIICs derived from the 
new LacZ hESC lines were evaluated for normal characteristics of primary 
ATIICs as described previously for SPCP.NEO.74 (ref. 10). As was shown for 
SPCP.NEO.74, hES-ATIICs derived from T1α.LacZ.53 and AQP5P.LacZ.65 
were morphologically normal containing lamellar bodies, which are char-
acteristic hallmarks of primary ATIICs. In addition, hES-ATIICs from these 
two new cell lines synthesized surfactant proteins A, B, and C as well as the 
complement proteins C3 and C5. They also expressed RNA specific for cys-
tic fibrosis transmembrane conductance regulator and α-1AT. To examine 
the ability of hES-ATIICs to proliferate in vitro, G418-selected hES-ATII 
cells were resuspended in mouse embryonic fibroblast–conditioned DMEM 
containing 10% fetal bovine serum with or without 30 ng/ml of rhKGF 
(R&D Systems, Minneapolis, MN) and plated on matrigel-coated 6-well 
plates (1.0 × 104/well). The medium was changed everyday for 8 days.
QRT-PCR analysis. Total RNA was isolated on days 0, 2, 4, 6, and 8 to ana-
lyze the expression of human ATIC phenotypic markers, T1α and AQP5, by 
QRT-PCR. Total RNA was isolated using RNA Bee (Tel-Test, Friendswood, 
TX). TaqMan One-Step RT-PCR Master Mix Kit (AB Applied Biosystems, 
Foster City, CA) was used for QRT-PCR analysis following manufacturer’s 
instructions employing 100 ng of total RNA for AQP5 and T1α and 100 pg 
of total RNA for endogenous control 18S with the following primers and 
probes: (i) AQP5 forward (5′-CCA TGG TGG TGG AGC TGA TTC TG-3′), 
AQP5 reverse (5′-TG CGG CGG GAG TCA GT-3′) and AQP5 probe (5′-6-
FAM-CTT CCA GCT GGC ACT CTG CAT CTT CGC C-TAMRA-3′); (ii) 
T1α forward (5′-GCT GCT TTG TTC TGG AAT ATG GAT ATC TC-3′), 
T1α reverse (5′-TTG AGC CTC TAG CAC CAT TAA GCA-3′) and T1α 
probe (5′-FAM-AGC AGC TTC CTC GGC ATC CAG G –TAMRA-3′); and 
(iii) 18S forward (5′-TAA CGA ACG AGA CTCTGG CAT-3′), 18S reverse 
(5′-CGG ACA TCT AAG GGC ATC ACA G-3′) and 18S probe (5′-FAM-
TGG CTG AAC GCC ACT TGT CCC TCT AA-TAMRA-3′). QRT-PCR 
was carried out at 48 °C for 30 minutes and 95 °C for 10 minutes followed 
by 40 cycles at 95 °C for 15 seconds and 60 °C for 1 minute in a 7900HT 
Sequence Detection Systems (AB Applied Biosystems).
Transplantation of hES-ATIICs into BLM-injured mouse lungs. To impair 
possible graft rejection of the hES-ATIICs, the BLM-induced acute 
lung injury model was established using immunodeficient SCID mice. 
Pathogen-free, 8- to 10-week-old, female SCID mice with body weights 
of 16–18 g, on a C57BL/6 genetic background (Jackson Laboratories, 
Bar Harbor, ME) received 50 μl of either BLM (3.5 units/kg; Bristol-
Myers Squibb, New York, NY) or sterile normal saline endotracheally 
via oropharynx intubation41 using a BioLITE Intubation Illumination 
System (Braintree Scientific, Braintree, MA). Oropharynx intubation 
required no surgery and thus no tracheal inflammation, thereby allow-
ing subsequent noninvasive administration of hES-ATII cells on days 1 
or 2 after BLM-challenge. The BLM-treated mice were transplanted with 
hES-ATIICs derived from the three different stable transfected hESC 
lines, SPCP.NEO.74, T1α.LacZ.53, and AQP5P.LacZ.65, at a dose of 0.5 
× 106 cells in 50 μl of sterile normal saline via an endotracheal catheter 
as above. Control mice received 50 μl of sterile normal saline or 0.5 × 106 
human monocytes. The body weights were determined every other day. 
BLM-exposed mice with or without transplantation of hES-ATII cells 
were killed on day 10 and lungs harvested for histological analysis. All 
mice were housed in a dedicated pathogen-free facility and cared for by 
a licensed veterinarian supervised staff. All experimental protocols were 
approved by the Institutional Animal Care and Use Committee of the 
University of Texas Health Science Center at Houston.
LacZ staining. The differentiating cultures of hES-ATIICs on days 0, 
2, 4, 6, and 8 were washed three times with phosphate-buffered saline 
(PBS) before fixation in 0.5% glutaraldehyde in PBS for 10 minutes at 
room temperature. After washing with PBS containing 1 mmol/l MgCl2, 
the cells were incubated overnight at 37 °C with X-gal solution com-
posed of 0.1% X-gal, 5 mmol/l potassium ferrocyanide, 5 mmol/l potas-
sium ferricyanide, and 1 mmol/l MgCl2 in PBS. β-Galactosidase activity 
was visualized with X-gal precipitates after washing with PBS. For LacZ 
staining of lung tissue,23 lungs which had been lavaged three times with 
500 μl of PBS containing 2 mmol/l MgCl2, were fixed for 10 minutes 
by instillation of 0.5% glutaraldehyde in PBS via a tracheal catheter. 
The fixative was removed by washing three times with PBS containing 
2 mmol/l MgCl2 through the tracheal catheter. Each lung was instilled 
with 500 μl of X-gal solution before tracheal ligation and then immersed 
in X-gal solution overnight at 37 °C. Lungs were fixed again in 4% para-
formaldehyde at 4 °C overnight, embedded in paraffin, and sectioned. 
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The lung sections were counterstained with Nuclear Fast Red (Vector 
Laboratories, Burlingame, CA) before mounting with Cytoseal (Richard 
Allan Scientific, Kalamazoo, MI).
Histological analysis and injury scoring of mouse lung tissues. On day 
10 after BLM-challenge, the mouse lungs were lavaged three times with 
500 μl of PBS, inflated, and fixed with 500 μl of 4% paraformaldehyde, and 
then immersed in the fixative solution at 4 °C overnight. After embedding 
in paraffin, tissue sections from the frontal, middle, and posterior coro-
nal planes were prepared on slides. Collagen deposition was evaluated by 
Sirius Red staining.42 Briefly, lung sections were incubated with 1% Sirius 
Red and 0.1% Fast Green FCF (Sigma, St Louis, MO) in saturated picric 
acid for 1 hour. The slides were then washed twice with 0.5% acetic acid in 
distilled H2O. The slides were then dehydrated and mounted with Cytoseal. 
Another set of slides from the same lung were stained with hematoxylin–
eosin for routine histology. BLM-induced lung damage was graded accord-
ing to the lung area (0, <10, 10–25, 25–50, 50–75, and >75%) involved with 
cellular infiltration, interstitial thickening, structure distortion as well as 
abnormal collagen deposition (n = 10 for experimental and control mice; 
at least two slides for each different plane/mouse).43
Hydroxyproline assay. Collagen deposition in the BLM-injured mouse 
lungs was also determined by analysis of hydroxyproline content by slight 
modification of a previously described method.44 Briefly, lungs were minced 
and homogenized in saline. An aliquot of homogenate was hydrolyzed in 
2 ml of 6 N HCl at 110 °C overnight, neutralized with 2 ml of 6 N NaOH, 
and filtered through a 0.45-mm nylon membrane. The samples (0.1 ml) 
were then incubated for 20 minutes at room temperature with 1 ml of 1.4% 
chloramine T (Sigma) containing 10% n-propanol, and 0.5 mol/l sodium 
acetate, pH 6.0. Ehrlich’s reagent (1 ml) was then added and incubated at 
65 °C for 15 minutes. Hydroxyproline content was measured at 550 nm 
against a standard curve.
Immunofluorescent staining and cell quantization. Lung section slides 
prepared as described above were deparaffinized, hydrated, and incu-
bated with 20 μg/ml proteinase K solution containing 50 mmol/l Tris 
and 1 mmol/l EDTA, pH 8.0 at 37 °C for 15 minutes. After rinsing twice 
in PBS-Tween (0.05% Tween-20 in PBS), slides were incubated in 1% 
Triton X-100 in PBS for 30 minutes before blocking for 1 hour with 5% 
of normal goat serum in PBS containing 0.2% Triton X-100. To block the 
endogenous mouse IgG, the sections were further incubated with 0.12 mg/
ml of unconjugated affiniPure Fab fragment goat anti-mouse IgG (H+L) 
(cat. no. 115-007-003; Jackson Laboratories) for 1 hour. To identify hES-
ATIICs, the sections were incubated with 1:10 diluted mouse antihuman 
nuclei monoclonal antibody and 1:100 diluted rabbit antihuman pro-SPC 
antibody (Chemicon, Temecula, CA) in PBS for 1 hour. The human nuclei 
and SPC+ cells were visualized with Alexa Fluor 546 F(ab′)2 fragment of 
goat anti-mouse IgG (H+L) and Alexa Fluor 488 F(ab′)2 fragment of goat 
anti rabbit IgG (H+L), respectively. The percentage of SPC+ cells that were 
also human nuclei+ were determined by visually counting 200–400 SPC+ 
cells in at least two slides per mouse lung (8 mice/group). The number and 
percentage of the counted SPC+ cells that were also human nuclei+ were 
then determined. The relative number of SPC−/human nuclei+ cells was 
determined by counting the number of SPC−/human nuclei+ cells were 
present in the exact area in which the SPC+ cells were counted. To deter-
mine whether any of the transplanted hES-ATIICs had differentiated into 
cells expressing the ATIC phenotypic marker T1α, immunofluorescent 
staining was performed with the mouse antihuman nuclei monoclonal 
antibody and a 1:50 diluted rabbit antihuman T1α antibody (Abgent, San 
Diego, CA), and secondary antibodies as above.
Measurements of lung tidal volume and blood arterial oxygen satura-
tion. The spontaneous lung tidal volume of BLM-injured mice with or 
without transplanted hES-ATIICs was recorded during normal respiration 
without ventilation using a rodent pulmonary plethysmograph model PLY 
3111 and a specifically designed software program designed for lung tidal 
volume analysis (Buxco Electronics, Sharon, CT). In addition, blood arte-
rial oxygen saturation was recorded using a small rodent oximeter sen-
sor mounted on the thigh of each tested mouse (MouseOX; STARR Life 
Sciences, Oakmont, PA). Data were collected for a minimum of 10 seconds 
without any error code for the two measured parameters, six measure-
ments (6 × 10 seconds) per mouse during a 3-minute period.
Statistical analysis. The data shown in Figures 2b, 5b,c, and 6a,b were 
analyzed statistically by the Student’s t-test (two-tailed) using Microsoft 
Excel software. P values <0.05 (α level = 0.05) were considered significant.
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